MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension

MCJ:肺动脉高压心脏干预的线粒体靶点

阅读:5
作者:Ayelén M Santamans ,Beatriz Cicuéndez ,Alfonso Mora ,María Villalba-Orero ,Sanela Rajlic ,María Crespo ,Paula Vo ,Madison Jerome ,Álvaro Macías ,Juan Antonio López ,Magdalena Leiva ,Susana F Rocha ,Marta León ,Elena Rodríguez ,Luis Leiva ,Aránzazu Pintor Chocano ,Inés García Lunar ,Ana García-Álvarez ,Pablo Hernansanz-Agustín ,Víctor I Peinado ,Joan Albert Barberá ,Borja Ibañez ,Jesús Vázquez ,Jessica B Spinelli ,Andreas Daiber ,Eduardo Oliver ,Guadalupe Sabio

Abstract

Pulmonary hypertension (PH) can affect both pulmonary arterial tree and cardiac function, often leading to right heart failure and death. Despite the urgency, the lack of understanding has limited the development of effective cardiac therapeutic strategies. Our research reveals that MCJ modulates mitochondrial response to chronic hypoxia. MCJ levels elevate under hypoxic conditions, as in lungs of patients affected by COPD, mice exposed to hypoxia, and myocardium from pigs subjected to right ventricular (RV) overload. The absence of MCJ preserves RV function, safeguarding against both cardiac and lung remodeling induced by chronic hypoxia. Cardiac-specific silencing is enough to protect against cardiac dysfunction despite the adverse pulmonary remodeling. Mechanistically, the absence of MCJ triggers a protective preconditioning state mediated by the ROS/mTOR/HIF-1α axis. As a result, it preserves RV systolic function following hypoxia exposure. These discoveries provide a potential avenue to alleviate chronic hypoxia-induced PH, highlighting MCJ as a promising target against this condition.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。